Zhang Shihan, Wang Yin, Xu Guo, Dong Chen, Tian Hua, Li Chuchu, Kong Xiaoxiao, Peng Jiefu, Huang Haodi, Simayi Aidibai, Zhu Fengcai, Hu Jianli, Xu Ke, Bao Changjun, Jin Hui, Zhu Liguo
Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China.
Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China.
Vaccines (Basel). 2024 Oct 25;12(11):1211. doi: 10.3390/vaccines12111211.
Previous SARS-CoV-2 infection provides some level of protection against reinfection. However, few studies have evaluated the neutralizing antibody (NAb) response after Delta variant infection and its ability to prevent reinfection with Omicron BA.5 one year later.
This prospective cohort study included 431 patients who recovered from Delta variant infection. We measured their serum NAb titers against both Delta and Omicron BA.5 using microneutralization tests.
Over a 17-month follow-up, 17.9% of the participants were reinfected with Omicron BA.5. Younger adults (18-65 years) and individuals who did not receive booster immunization had significantly higher reinfection rates than older adults (>65 years) and those who received boosters ( < 0.05). Notably, reinfection rates were higher in post-vaccination breakthrough cases than in individuals who were naturally infected. However, booster immunization reduced reinfection rates within the breakthrough group. We found no significant association between Delta NAb levels and protection against Omicron BA.5 reinfection ( > 0.05). Cross-neutralization assays showed a 7.1-fold reduction in NAb efficacy against Omicron BA.5.
Delta-variant infection-induced NAbs did not strongly predict protection against Omicron BA.5 reinfection. However, booster immunization effectively reduced the reinfection rate approximately one year after the initial Delta infection.
既往感染过严重急性呼吸综合征冠状病毒2(SARS-CoV-2)可提供一定程度的再次感染防护。然而,很少有研究评估感染德尔塔变异株后的中和抗体(NAb)反应及其在一年后预防感染奥密克戎BA.5的能力。
这项前瞻性队列研究纳入了431例从德尔塔变异株感染中康复的患者。我们使用微量中和试验测量了他们针对德尔塔和奥密克戎BA.5的血清NAb滴度。
在17个月的随访中,17.9%的参与者再次感染了奥密克戎BA.5。较年轻的成年人(18 - 65岁)和未接受加强免疫的个体的再次感染率显著高于较年长的成年人(>65岁)和接受加强免疫的个体(<0.05)。值得注意的是,疫苗接种突破病例中的再次感染率高于自然感染的个体。然而,加强免疫降低了突破组内的再次感染率。我们发现德尔塔NAb水平与预防奥密克戎BA.5再次感染的保护作用之间无显著关联(>0.05)。交叉中和试验显示针对奥密克戎BA.5的NAb效力降低了7.1倍。
感染德尔塔变异株诱导产生的NAb并不能有力预测对奥密克戎BA.5再次感染的保护作用。然而在初次感染德尔塔变异株约一年后,加强免疫有效降低了再次感染率。